Richard L. McGough
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Richard L. McGough has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Kurt Weiss
Department of Orthopedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
3 shared publications - Karen Elizabeth Schoedel
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
2 shared publications Mark A. Goodman
2 shared publications- Matthew F. Gong
Department of Orthopaedic Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
2 shared publications - Stella J. Lee
Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
2 shared publications Steven W. Thorpe
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
Survival and Reoperation After Intralesional Procedures Versus Resection and Reconstruction for Renal Cell Carcinoma Bone Metastases
Background: The management of renal cell carcinoma (RCC) long-bone metastases often involves surgery with either resection and reconstruction (R&R) or intralesional (IL) procedures. Some literature suggests that R&R improves survival and reduces the risk of recurrence and reoperation, while IL procedures offer lower surgical morbidity and faster recovery. We compared survival and reoperation outcomes following IL versus R&R procedures for RCC long-bone metastases treated at our institution. Methods: We retrospectively reviewed patients with histologically confirmed RCC long-bone metastases treated surgically between July 1, 2005, and June 1, 2022. Medical charts were reviewed to collect data on demographics, treatment history, and outcomes. Multivariable Cox proportional-hazards regression and Fine-Gray competing-risks regression were used to evaluate survival and reoperation following IL and R&R procedures. Results: One hundred and five patients (68% male; mean age, 62.6 years; 96% White) with 133 metastases were included. IL surgery was not significantly associated with a greater cumulative incidence of reoperation (subdistribution hazard ratio [sHR] = 1.08, p = 0.87). Reoperations were primarily due to recurrent disease (29%) and pathologic fracture (33%) in the IL group, compared with recurrent disease (29%), pathologic fracture (14%), and wound infection (14%) in the R&R group. IL surgery was associated with a greater hazard of mortality in the overall cohort (HR = 2.03, p = 0.02), although no significant association was observed in the solitary metastasis subgroup (HR = 1.54, p = 0.49). Conclusions: IL procedures were associated with greater mortality, although this association was not observed among patients with a solitary metastasis. Given no significant difference in the cumulative incidence of reoperation between surgical approaches, IL and R&R procedures are both reasonable treatment options in appropriately selected patients and clinical settings. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
- 7 October 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
Open AccessSurvival and Reoperation After Intralesional Procedures Versus Resection and Reconstruction for Renal Cell Carcinoma Bone Metastases
Background: The management of renal cell carcinoma (RCC) long-bone metastases often involves surgery with either resection and reconstruction (R&R) or intralesional (IL) procedures. Some literature suggests that R&R improves survival and reduces the risk of recurrence and reoperation, while IL procedures offer lower surgical morbidity and faster recovery. We compared survival and reoperation outcomes following IL versus R&R procedures for RCC long-bone metastases treated at our institution. Methods: We retrospectively reviewed patients with histologically confirmed RCC long-bone metastases treated surgically between July 1, 2005, and June 1, 2022. Medical charts were reviewed to collect data on demographics, treatment history, and outcomes. Multivariable Cox proportional-hazards regression and Fine-Gray competing-risks regression were used to evaluate survival and reoperation following IL and R&R procedures. Results: One hundred and five patients (68% male; mean age, 62.6 years; 96% White) with 133 metastases were included. IL surgery was not significantly associated with a greater cumulative incidence of reoperation (subdistribution hazard ratio [sHR] = 1.08, p = 0.87). Reoperations were primarily due to recurrent disease (29%) and pathologic fracture (33%) in the IL group, compared with recurrent disease (29%), pathologic fracture (14%), and wound infection (14%) in the R&R group. IL surgery was associated with a greater hazard of mortality in the overall cohort (HR = 2.03, p = 0.02), although no significant association was observed in the solitary metastasis subgroup (HR = 1.54, p = 0.49). Conclusions: IL procedures were associated with greater mortality, although this association was not observed among patients with a solitary metastasis. Given no significant difference in the cumulative incidence of reoperation between surgical approaches, IL and R&R procedures are both reasonable treatment options in appropriately selected patients and clinical settings. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
- Open Access
- 24 March 2025
- Published by Wolters Kluwer Health in JAAOS: Global Research and Reviews
- Vol. 9 (4)
Rating the Efficacy of Diagnostic Imaging Studies Conducted for the Workup of Musculoskeletal Tumors
Background: Concerns for missed diagnoses have led to increased ordering of diagnostic imaging. Patients with suspected musculoskeletal tumors may undergo nondiagnostic and unnecessary imaging studies before referral to a musculoskeletal oncologist. This can result in patients receiving excessive radiation exposures, accruing unnecessary costs, delays in treatment, and an unnecessary burden on healthcare systems. Purpose: The purposes of this study were to (1) internally rate the usefulness of imaging tests completed for musculoskeletal oncology patients undergoing evaluation using a novel scoring system, (2) determine the inter-rater reliability of providers who rated imaging tests, and (3) assess the costs incurred for imaging studies based on Medicare reimbursement rates. Methods: A single-center, retrospective study was conducted on 112 patients who presented to our musculoskeletal oncology clinic for workup of a suspected mass from February 2021 to May 2021. After obtaining institutional review board approval, information regarding all radiographic images pertinent to the patient's workup was collected through a manual chart review. Patient information and images were sent to six fellowship-trained physicians for review. Providers then graded the appropriateness of each study using a five-point rating system. Final diagnoses were divided into three categories: bone lesions, soft-tissue lesions, and metastatic skeletal lesions. Inter-rater reliability was assessed using interclass correlation coefficient tests. The cost of wasteful tests was calculated using Medicare reimbursement rates. Results: Three hundred twenty-two imaging studies conducted on 112 patients were included in the study. For primary bone lesions, plain radiographs and MRI scans with and without contrast were the highest rated diagnostic studies. For soft-tissue lesions, MRI and CT scans without contrast were the highest rated diagnostic studies. For metastatic bone lesions, positron emission tomography/CT and MRI scans with and without contrast were highly rated diagnostic studies. For all tumor types, core needle biopsy was the highest rated invasive study. The overall interclass correlation coefficient between all providers was 0.33. 1.2% of studies ordered by our department were considered wasteful, accounting for around $1,775 (2.3%) of costs. Conclusion: Our study was conducted to internally rate the usefulness of imaging tests ordered for patients who presented to a musculoskeletal oncology clinic. For all tumor types, MRI, CT, and plain radiographs were frequently rated as helpful studies. Core needle biopsy was the highest rated invasive study. Bone scans were considered of limited utility for most bone lesions. The quantity of wasteful studies was low overall. Our study demonstrates the complexity in obtaining appropriate diagnostic imaging for the evaluation of musculoskeletal tumors.
- 24 March 2025
- Published by Wolters Kluwer Health in JAAOS: Global Research and Reviews
- Vol. 9 (4)
Open AccessRating the Efficacy of Diagnostic Imaging Studies Conducted for the Workup of Musculoskeletal Tumors
Background: Concerns for missed diagnoses have led to increased ordering of diagnostic imaging. Patients with suspected musculoskeletal tumors may undergo nondiagnostic and unnecessary imaging studies before referral to a musculoskeletal oncologist. This can result in patients receiving excessive radiation exposures, accruing unnecessary costs, delays in treatment, and an unnecessary burden on healthcare systems. Purpose: The purposes of this study were to (1) internally rate the usefulness of imaging tests completed for musculoskeletal oncology patients undergoing evaluation using a novel scoring system, (2) determine the inter-rater reliability of providers who rated imaging tests, and (3) assess the costs incurred for imaging studies based on Medicare reimbursement rates. Methods: A single-center, retrospective study was conducted on 112 patients who presented to our musculoskeletal oncology clinic for workup of a suspected mass from February 2021 to May 2021. After obtaining institutional review board approval, information regarding all radiographic images pertinent to the patient's workup was collected through a manual chart review. Patient information and images were sent to six fellowship-trained physicians for review. Providers then graded the appropriateness of each study using a five-point rating system. Final diagnoses were divided into three categories: bone lesions, soft-tissue lesions, and metastatic skeletal lesions. Inter-rater reliability was assessed using interclass correlation coefficient tests. The cost of wasteful tests was calculated using Medicare reimbursement rates. Results: Three hundred twenty-two imaging studies conducted on 112 patients were included in the study. For primary bone lesions, plain radiographs and MRI scans with and without contrast were the highest rated diagnostic studies. For soft-tissue lesions, MRI and CT scans without contrast were the highest rated diagnostic studies. For metastatic bone lesions, positron emission tomography/CT and MRI scans with and without contrast were highly rated diagnostic studies. For all tumor types, core needle biopsy was the highest rated invasive study. The overall interclass correlation coefficient between all providers was 0.33. 1.2% of studies ordered by our department were considered wasteful, accounting for around $1,775 (2.3%) of costs. Conclusion: Our study was conducted to internally rate the usefulness of imaging tests ordered for patients who presented to a musculoskeletal oncology clinic. For all tumor types, MRI, CT, and plain radiographs were frequently rated as helpful studies. Core needle biopsy was the highest rated invasive study. Bone scans were considered of limited utility for most bone lesions. The quantity of wasteful studies was low overall. Our study demonstrates the complexity in obtaining appropriate diagnostic imaging for the evaluation of musculoskeletal tumors.
- Open Access
Intraoperative Evaluation of Soft Tissue Sarcoma Surgical Margins with Indocyanine Green Fluorescence Imaging
Soft tissue sarcomas (STS) are rare malignant tumors often associated with poor outcomes and high local recurrence rates. Current tools for intraoperative and definitive margin assessment include intraoperative frozen section and permanent pathology, respectively. Indocyanine green dye (ICG) is a historically safe fluorophore dye that has demonstrated efficacy for intraoperative margin assessment in the surgical management of both breast and gastrointestinal cancers. The utility of ICG in the surgical management of sarcoma surgery has primarily been studied in pre-clinical mouse models and warrants further investigation as a potential adjunct to achieving negative margins. This study is a prospective, non-randomized clinical study conducted on patients with confirmed or suspected STS. Patients younger than 18 years, with a prior adverse reaction to iodine or fluorescein, or with renal disease were excluded from the study. Intravenous ICG was infused approximately three hours prior to surgery at a dosage of 2.0–2.5 mg/kg, and following tumor resection, the excised tumor and tumor bed were imaged for fluorescence intensity. When scanning the tumor bed, a threshold of 77% calibrated to the region of maximum intensity in the resected tumor was defined as a positive ICG margin, according to published protocols from the breast cancer literature. ICG results were then compared with the surgeon’s clinical impression of margin status and permanent pathology results. Out of 26 subjects recruited for the original study, 18 soft tissue sarcomas (STS) were included for analysis. Three subjects were excluded for having bone sarcomas, and five subjects were excluded due to final pathology, which was ultimately inconsistent with sarcoma. The average age of patients was 64.1 years old (range: 28–83), with an average ICG dose of 201.8 mg. In 56% (10/18) of patients, ICG margins were consistent with the permanent pathology margins, with 89% specificity. The use of ICG as an intraoperative adjunct to obtaining negative margins in soft tissue sarcoma surgery is promising. However, studies with larger sample sizes are warranted to further delineate the accuracy, optimal dosage, timing, and types of sarcoma in which this diagnostic tool may be most useful.
Open AccessIntraoperative Evaluation of Soft Tissue Sarcoma Surgical Margins with Indocyanine Green Fluorescence Imaging
Soft tissue sarcomas (STS) are rare malignant tumors often associated with poor outcomes and high local recurrence rates. Current tools for intraoperative and definitive margin assessment include intraoperative frozen section and permanent pathology, respectively. Indocyanine green dye (ICG) is a historically safe fluorophore dye that has demonstrated efficacy for intraoperative margin assessment in the surgical management of both breast and gastrointestinal cancers. The utility of ICG in the surgical management of sarcoma surgery has primarily been studied in pre-clinical mouse models and warrants further investigation as a potential adjunct to achieving negative margins. This study is a prospective, non-randomized clinical study conducted on patients with confirmed or suspected STS. Patients younger than 18 years, with a prior adverse reaction to iodine or fluorescein, or with renal disease were excluded from the study. Intravenous ICG was infused approximately three hours prior to surgery at a dosage of 2.0–2.5 mg/kg, and following tumor resection, the excised tumor and tumor bed were imaged for fluorescence intensity. When scanning the tumor bed, a threshold of 77% calibrated to the region of maximum intensity in the resected tumor was defined as a positive ICG margin, according to published protocols from the breast cancer literature. ICG results were then compared with the surgeon’s clinical impression of margin status and permanent pathology results. Out of 26 subjects recruited for the original study, 18 soft tissue sarcomas (STS) were included for analysis. Three subjects were excluded for having bone sarcomas, and five subjects were excluded due to final pathology, which was ultimately inconsistent with sarcoma. The average age of patients was 64.1 years old (range: 28–83), with an average ICG dose of 201.8 mg. In 56% (10/18) of patients, ICG margins were consistent with the permanent pathology margins, with 89% specificity. The use of ICG as an intraoperative adjunct to obtaining negative margins in soft tissue sarcoma surgery is promising. However, studies with larger sample sizes are warranted to further delineate the accuracy, optimal dosage, timing, and types of sarcoma in which this diagnostic tool may be most useful.
- 8 March 2017
- Published by Springer Nature in Der Unfallchirurg
- Vol. 120 (4) , 300-305
The Compress® transcutaneous implant for rehabilitation following limb amputation
Amputation is an unfortunate outcome of a variety of orthopedic conditions. Many amputees can be functionally fitted with conventional suspension sockets. A substantial subset, however, fails this conventional treatment and is unable to function. In Europe, an alternative to socket-based prostheses has been available for 25 years. Patients there who are unable to functionally use socket-based prostheses have been offered the possibility for transcutaneous osseointegration. With this technology, the prosthetic limb can be rigidly attached to the residual bone, and the socket is eliminated, in many cases enabling improved function and patient satisfaction. In the United States, regulatory barriers have greatly limited the adoption and acceptance of transdermal osseointegration. The Compress® device was developed as an alternate means of fixation for massive endoprostheses, such as distal femoral replacements. A uniquely designed prosthesis is rigidly anchored to the end of the cortical bone and is then subjected to a large axial stress. The bone then grows avidly into the device, providing permanent osseointegration. We have recently adopted this device for transcutaneous use. These procedures have been performed in the United States on a custom regulatory basis. Results of this have been encouraging, and we are planning to begin a regulatory trial in the near future. Die Amputation ist bedauerliches Ergebnis einer Anzahl orthopädischer Erkrankungen. Viele Patienten können nach Amputation mit herkömmlichen Schaftprothesen funktionell ausgestattet werden. Bei einem wesentlichen Anteil aber gelingt die funktionelle Versorgung mit dieser herkömmlichen Therapie nicht. In Europa ist seit 25 Jahren eine Alternative zur Schaftprothese verfügbar. Patienten, bei denen die funktionelle Verwendung einer Schaftprothese nicht möglich ist, wurde die Option einer transkutanen Osseointegration angeboten. Mit diesem Verfahren kann die Extremitätenprothese fest an dem verbliebenen Knochen verankert werden, und der Schaft wird weggelassen, was in vielen Fällen zu einer besseren Funktion und größeren Patientenzufriedenheit führt. In den Vereinigten Staaten haben regulatorische Hürden die Einführung und Akzeptanz der transdermalen Osseointegration weitgehend beschränkt. Die Compress®-Prothese wurde als alternative Methode zur Fixierung großer Endoprothesen entwickelt, z. B. für den Ersatz des distalen Femurs. Eine speziell angefertigte Prothese wird fest im Ende des kortikalen Knochens verankert und dann einer großen axialen Belastung ausgesetzt. Der Knochen wächst somit rege in das Implantat ein, was zu einer dauerhaften Knochenverankerung führt. Vor Kurzem wurde dieses System für den transkutanen Einsatz angepasst. Diese Operationen sind in den Vereinigten Staaten jeweils auf einer individuellen regulatorischen Grundlage durchgeführt worden. Die Ergebnisse waren ermutigend, und die Autoren planen, in naher Zukunft mit einer Zulassungsstudie anzufangen.
- 8 March 2017
- Published by Springer Nature in Der Unfallchirurg
- Vol. 120 (4) , 300-305
The Compress® transcutaneous implant for rehabilitation following limb amputation
Amputation is an unfortunate outcome of a variety of orthopedic conditions. Many amputees can be functionally fitted with conventional suspension sockets. A substantial subset, however, fails this conventional treatment and is unable to function. In Europe, an alternative to socket-based prostheses has been available for 25 years. Patients there who are unable to functionally use socket-based prostheses have been offered the possibility for transcutaneous osseointegration. With this technology, the prosthetic limb can be rigidly attached to the residual bone, and the socket is eliminated, in many cases enabling improved function and patient satisfaction. In the United States, regulatory barriers have greatly limited the adoption and acceptance of transdermal osseointegration. The Compress® device was developed as an alternate means of fixation for massive endoprostheses, such as distal femoral replacements. A uniquely designed prosthesis is rigidly anchored to the end of the cortical bone and is then subjected to a large axial stress. The bone then grows avidly into the device, providing permanent osseointegration. We have recently adopted this device for transcutaneous use. These procedures have been performed in the United States on a custom regulatory basis. Results of this have been encouraging, and we are planning to begin a regulatory trial in the near future. Die Amputation ist bedauerliches Ergebnis einer Anzahl orthopädischer Erkrankungen. Viele Patienten können nach Amputation mit herkömmlichen Schaftprothesen funktionell ausgestattet werden. Bei einem wesentlichen Anteil aber gelingt die funktionelle Versorgung mit dieser herkömmlichen Therapie nicht. In Europa ist seit 25 Jahren eine Alternative zur Schaftprothese verfügbar. Patienten, bei denen die funktionelle Verwendung einer Schaftprothese nicht möglich ist, wurde die Option einer transkutanen Osseointegration angeboten. Mit diesem Verfahren kann die Extremitätenprothese fest an dem verbliebenen Knochen verankert werden, und der Schaft wird weggelassen, was in vielen Fällen zu einer besseren Funktion und größeren Patientenzufriedenheit führt. In den Vereinigten Staaten haben regulatorische Hürden die Einführung und Akzeptanz der transdermalen Osseointegration weitgehend beschränkt. Die Compress®-Prothese wurde als alternative Methode zur Fixierung großer Endoprothesen entwickelt, z. B. für den Ersatz des distalen Femurs. Eine speziell angefertigte Prothese wird fest im Ende des kortikalen Knochens verankert und dann einer großen axialen Belastung ausgesetzt. Der Knochen wächst somit rege in das Implantat ein, was zu einer dauerhaften Knochenverankerung führt. Vor Kurzem wurde dieses System für den transkutanen Einsatz angepasst. Diese Operationen sind in den Vereinigten Staaten jeweils auf einer individuellen regulatorischen Grundlage durchgeführt worden. Die Ergebnisse waren ermutigend, und die Autoren planen, in naher Zukunft mit einer Zulassungsstudie anzufangen.
- 1 June 2014
- Published by Elsevier in Operative Techniques in Orthopaedics
- Vol. 24 (2) , 62-67
The Role of the Orthopaedic Oncologist in Chest Wall Resections and Reconstructions
- 1 June 2014
- Published by Elsevier in Operative Techniques in Orthopaedics
- Vol. 24 (2) , 62-67
The Role of the Orthopaedic Oncologist in Chest Wall Resections and Reconstructions
- 1 December 2012
- Published by Elsevier in Operative Techniques in Orthopaedics
- Vol. 22 (4) , 228-235
Coping with Extensive Bone Loss: The Use of Megaprosthetic Replacements for Difficult Knee Revisions
- 1 December 2012
- Published by Elsevier in Operative Techniques in Orthopaedics
- Vol. 22 (4) , 228-235
Coping with Extensive Bone Loss: The Use of Megaprosthetic Replacements for Difficult Knee Revisions
- 1 September 2012
- Published by Wolters Kluwer Health in Current Orthopaedic Practice
- Vol. 23 (5) , 467-472
Expanding the scope of the orthopaedic oncology practice
Background: Few studies exist discussing the orthopaedic oncologist's role with resection of chest wall tumors. The primary goal of this study was to evaluate our experience and outcomes with resection and reconstruction of chest wall tumors. Methods: A retrospective review of patients who underwent resection of benign or malignant chest wall tumors at our institution between 1992 and 2009 was conducted. Only resections of the bony thorax were included. Median follow-up was 25 months (range 1–227 months). Results: Twenty-five patients underwent bony thoracic resection at our institution. Three of these patients had benign tumors: giant cell tumor, chondromyxoid fibroma, and an osteochondroma causing dysphagia. Thoracic or pediatric surgeons assisted in 16 of these cases. Plastic surgery assisted with soft-tissue reconstruction in eight cases. Only five of 22 (23%) patients with a malignant tumor had a positive margin at the time of resection. The 5-year and 10-year survival based on Kaplan-Meier Survival curve was 83%. Patients with chondrosarcoma had a significantly greater recurrence-free survival than all other malignant histiotypes (83% compared with 50%). Respiratory complications were minimal, with 52% extubated on the day of surgery and an average time until extubation of 1.7 days. Six patients had chronic pain at latest follow-up. Conclusions: While rarely a substantial portion of orthopaedic residency or even musculoskeletal oncology fellowship training, resections of the bony thorax can be performed successfully and safely by orthopaedic oncologists. By following appropriate sarcoma principles, optimal results can be obtained with minimal perioperative morbidity.
- 1 September 2012
- Published by Wolters Kluwer Health in Current Orthopaedic Practice
- Vol. 23 (5) , 467-472
Expanding the scope of the orthopaedic oncology practice
Background: Few studies exist discussing the orthopaedic oncologist's role with resection of chest wall tumors. The primary goal of this study was to evaluate our experience and outcomes with resection and reconstruction of chest wall tumors. Methods: A retrospective review of patients who underwent resection of benign or malignant chest wall tumors at our institution between 1992 and 2009 was conducted. Only resections of the bony thorax were included. Median follow-up was 25 months (range 1–227 months). Results: Twenty-five patients underwent bony thoracic resection at our institution. Three of these patients had benign tumors: giant cell tumor, chondromyxoid fibroma, and an osteochondroma causing dysphagia. Thoracic or pediatric surgeons assisted in 16 of these cases. Plastic surgery assisted with soft-tissue reconstruction in eight cases. Only five of 22 (23%) patients with a malignant tumor had a positive margin at the time of resection. The 5-year and 10-year survival based on Kaplan-Meier Survival curve was 83%. Patients with chondrosarcoma had a significantly greater recurrence-free survival than all other malignant histiotypes (83% compared with 50%). Respiratory complications were minimal, with 52% extubated on the day of surgery and an average time until extubation of 1.7 days. Six patients had chronic pain at latest follow-up. Conclusions: While rarely a substantial portion of orthopaedic residency or even musculoskeletal oncology fellowship training, resections of the bony thorax can be performed successfully and safely by orthopaedic oncologists. By following appropriate sarcoma principles, optimal results can be obtained with minimal perioperative morbidity.
- 1 August 2010
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 468 (8) , 2067-2073
Outcomes of Revision Total Knee Arthroplasty After Methicillin-resistant Staphylococcus aureus Infection
Nfections are associated with decreased functional scores. Questions/purposes We therefore compared the functional scores, operative times, and rates of reinfection of revision TKA following MRSA infection versus other indications for revision. Methods We retrospectively reviewed charts of 101 patients (103 knees) who underwent mobile bearing TKA revision from January 2003 to September 2006, with a minimum clinical followup of 2 years in 45 knees (44%). We obtained the following indices: WOMAC, Activities of Daily Living Score (ADLS), SF-36, and Knee Society scores (KSS). Three groups of revisions were compared: MRSA infection (n = 6), non-MRSA infection (n = 9), and aseptic failure (n = 30). The three groups were similar in demographics and comorbidities. Results The MRSA (166 minutes) and non-MRSA groups (149 minutes) had longer operative times than the aseptic group (121 minutes). With numbers available, there were no differences in ROM, WOMAC, ADLS, KSS, and SF-36, with MRSA separate or combined with all infections. Infection recurrence between MRSA-infected knees and non-MRSA-infected knees was similar. Conclusions While our study was underpowered to detect functional differences between MRSA-infected knees and non-MRSA-infected knees it does add data to the literature. Knees revised for infection have longer operative times and more frequent infection after revision. The reason for increased operative times is unclear. Level of Evidence Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence....
- 1 August 2010
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 468 (8) , 2067-2073
Outcomes of Revision Total Knee Arthroplasty After Methicillin-resistant Staphylococcus aureus Infection
Nfections are associated with decreased functional scores. Questions/purposes We therefore compared the functional scores, operative times, and rates of reinfection of revision TKA following MRSA infection versus other indications for revision. Methods We retrospectively reviewed charts of 101 patients (103 knees) who underwent mobile bearing TKA revision from January 2003 to September 2006, with a minimum clinical followup of 2 years in 45 knees (44%). We obtained the following indices: WOMAC, Activities of Daily Living Score (ADLS), SF-36, and Knee Society scores (KSS). Three groups of revisions were compared: MRSA infection (n = 6), non-MRSA infection (n = 9), and aseptic failure (n = 30). The three groups were similar in demographics and comorbidities. Results The MRSA (166 minutes) and non-MRSA groups (149 minutes) had longer operative times than the aseptic group (121 minutes). With numbers available, there were no differences in ROM, WOMAC, ADLS, KSS, and SF-36, with MRSA separate or combined with all infections. Infection recurrence between MRSA-infected knees and non-MRSA-infected knees was similar. Conclusions While our study was underpowered to detect functional differences between MRSA-infected knees and non-MRSA-infected knees it does add data to the literature. Knees revised for infection have longer operative times and more frequent infection after revision. The reason for increased operative times is unclear. Level of Evidence Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence....
- Open Access
- 24 November 2007
- Published by Springer Nature in Diagnostic Pathology
- Vol. 2 (1) , 44
Chondromyxoid fibroma of rib with a novel chromosomal translocation: a report of four additional cases at unusual sites
Background: Chondromyxoid fibromas (CMFs) are rare benign chondroid/myxoid matrix-producing tumors that occur in metaphyses of long tubular bones, and very rarely in small bones of hands and feet. Flat bone involvement is even more uncommon. Prior cytogenetic analyses have identified complex abnormalities involving chromosome 6 in the majority of cases.Methods: A search for CMF over an 8-year period (1999–2006) from the surgical pathology files of our institution yielded 16 cases. Four cases occurred in relatively unusual regions, three from the small bones of distal extremities and one from the rib. The rib lesion wassubmitted forroutinecytogenetic analysis.Results: Radiographic studies revealed that all four lesions were well-defined expansile radiolucent lesions which expanded the bony cortices with lobulated margins, sclerotic rim, septation, and no calcification. Morphologically, all four lesions showed typical features of CMF and had low proliferative index with Ki-67. Cytogenetic analysis on the rib lesion revealed a novel chromosomal translocation, t(1;5)(p13;p13). None of the four patients had a recurrence after a mean duration of follow-up of 24 months.Conclusion: CMF originating in unusual locations should be distinguished from chondrosarcomas, especially on small biopsies, and should be included in the differential diagnosis. As previously noted in the literature, the cells can be positive for actin but unlike conventional chondroid neoplasms can be negative for S-100. To our knowledge, this is the first report describing a novel chromosomal translocation, t(1;5)(p13;p13) in CMF.
- 24 November 2007
- Published by Springer Nature in Diagnostic Pathology
- Vol. 2 (1) , 44
Open AccessChondromyxoid fibroma of rib with a novel chromosomal translocation: a report of four additional cases at unusual sites
Background: Chondromyxoid fibromas (CMFs) are rare benign chondroid/myxoid matrix-producing tumors that occur in metaphyses of long tubular bones, and very rarely in small bones of hands and feet. Flat bone involvement is even more uncommon. Prior cytogenetic analyses have identified complex abnormalities involving chromosome 6 in the majority of cases.Methods: A search for CMF over an 8-year period (1999–2006) from the surgical pathology files of our institution yielded 16 cases. Four cases occurred in relatively unusual regions, three from the small bones of distal extremities and one from the rib. The rib lesion wassubmitted forroutinecytogenetic analysis.Results: Radiographic studies revealed that all four lesions were well-defined expansile radiolucent lesions which expanded the bony cortices with lobulated margins, sclerotic rim, septation, and no calcification. Morphologically, all four lesions showed typical features of CMF and had low proliferative index with Ki-67. Cytogenetic analysis on the rib lesion revealed a novel chromosomal translocation, t(1;5)(p13;p13). None of the four patients had a recurrence after a mean duration of follow-up of 24 months.Conclusion: CMF originating in unusual locations should be distinguished from chondrosarcomas, especially on small biopsies, and should be included in the differential diagnosis. As previously noted in the literature, the cells can be positive for actin but unlike conventional chondroid neoplasms can be negative for S-100. To our knowledge, this is the first report describing a novel chromosomal translocation, t(1;5)(p13;p13) in CMF.